Tag Archives: RRMS

May, 2017

8 May
Teva and Active Biotech’s Laquinimod Fails to Meet Primary Endpoint in Phase 3 Multiple Sclerosis Trial

JERUSALEM & LUND, Sweden–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS). The primary endpoint in CONCERTO — the evaluation of laquinimod (0.6 mg/daily capsules) versus placebo to evaluate …
Share

13 January
The MS Game Changer

A new medication for multiple sclerosis made waves when research about its effectiveness debuted at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) back in October 2015. Now experts are calling this medication one of the greatest developments of the past year for the …
Share
4 January
Teva and Active Biotech Discontinue Trials Evaluating Higher Doses of Oral MS Drug

JERUSALEM & LUND, Sweden–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ Stockholm:ACTI) today announced the discontinuation of higher doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients. The change comes …
Share

14 December
Akaal Pharma’s Drug Candidate Demonstrates Superior Safety & Comparable Efficacy Compared to Gilenya for Treatment of MS

MELBOURNE, Australia & SAN DIEGO–(BUSINESS WIRE)–Akaal Pharma, a clinical-stage drug discovery and development company, today announced the publication of preclinical studies of safety and efficacy of its novel small molecule drug candidate AKP-11 in comparison with Gilenya (Fingolimod, FTY-720). Gilenya is a FDA approved oral drug for the treatment of …
Share